JohnM.HoffmanMD

Clinical Trials

• Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response Start of enrollment: 2007 Sep 01

  Completed

  Phase 1

• FDG-Positron Emission Tomography (PET)/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients Start of enrollment: 2007 Aug 21

  Terminated

  Phase 1

• [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors Start of enrollment: 2007 Oct 31

  Completed

  Phase 1

• A Multi-modality Imaging Assessment of Chemobrain Start of enrollment: 2007 May 09

  Completed

  Phase 1

• Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients Start of enrollment: 2008 Mar 28

  Completed

  Phase 1

• Multi-Tracer PET Assessment of Primary Brain Tumors Start of enrollment: 2010 Nov 12

  Completed

  Phase 1

• 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01

  Active, not recruiting

  Phase 2

• F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Start of enrollment: 2009 Jan 01

  Unknown status

  Phase 3

• Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors Start of enrollment: 2011 Feb 02

  Terminated

  Not Applicable

• Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water Start of enrollment: 2013 Mar 27

  Terminated

  Phase 1

• Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab Start of enrollment: 2018 Jan 01

  Withdrawn

  Phase 2

• Join now to see all